DAVI DAVION HEALTHCARE PLC
Price Chart
Executive Summary
Davion Healthcare Plc filed its 20-F annual report for FY2025, confirming it remains a pre-revenue company with no commercial sales to date. The company reported an operating loss of €0.8 million for 2025 (improved from €1.3 million in 2024) and ended the year with only €1,058 in cash, relying on CEO advances of €0.9 million and a letter of support from Malbrite Ltd for the next 12 months. The key development is the global licensing agreement with NeuRX Health Inc. for BreastCheck, valued at $220 million over 10 years, with first commercial launch expected in H2 2026, but the company also disclosed a material weakness in internal controls and the need for a restatement of prior financials.
Actionable Insight
Monitor for Nasdaq listing clearance and the NeuRX BreastCheck commercial launch in H2 2026, which is the primary revenue catalyst. The $1.5M convertible note and $2.0M term loan facility provide near-term liquidity but add dilution risk. The material weakness in internal controls and restatement history warrant caution until remediation is demonstrated.
Key Facts
- Pre-revenue company with no commercial sales; operating loss of €0.8 million in 2025 (vs €1.3 million in 2024)
- Cash and cash equivalents of only €1,058 as of December 31, 2025
- CEO Jack Kaye owed €0.9 million in advances; Malbrite Ltd provided letter of financial support for 12 months
- Global licensing agreement with NeuRX Health Inc. for BreastCheck: $120 million license fee ($20M cash + $100M in NeuRX shares over 10 years) plus minimum annual royalties of $10 million
- BreastCheck commercial launch expected in H2 2026; no other license agreements for other products
- Material weakness in internal control over financial reporting identified; restatement of 2024 and 2023 financials required
- Post-period: $1.5 million secured convertible note issued (March 2026); $2.0 million committed term loan facility (March 2026)
- Intangible assets of €65.0 million (intellectual property) not impaired; indefinite useful life maintained
- No revenue recognized in 2025; revenue recognition policy adopted for licensing arrangement
- Company awaiting Nasdaq listing clearance; registration statement effective November 28, 2025
Financial Impact
Operating loss of €0.8 million in 2025; cash position of €1,058; CEO advances of €0.9 million; licensing agreement valued at $220 million over 10 years
Risk Factors
- Pre-revenue with minimal cash; dependent on CEO support and NeuRX performance for survival
- Single-licensee concentration risk for BreastCheck; no other license agreements for remaining products
- Material weakness in internal controls may delay reporting or lead to further restatements
- Dilution risk from convertible note (139,925 shares) and advisory share issuances (225,000 shares)
- Intellectual property impairment risk if commercialization is delayed or fails
- Geopolitical and macroeconomic risks could impact consumer adoption and supply chains
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001683168-26-003389 |
| Document: davion_ex1011.htm | 0001683168-26-003389 |
| Document: davion_ex9701.htm | 0001683168-26-003389 |
| Document: davion_ex1010.htm | 0001683168-26-003389 |
| Document: davion_ex1012.htm | 0001683168-26-003389 |
| Document: davion_ex1100.htm | 0001683168-26-003389 |
| Document: davion_ex3102.htm | 0001683168-26-003389 |
| Document: davion_ex9904.htm | 0001683168-26-003389 |
| Document: davion_ex3101.htm | 0001683168-26-003389 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access